ARCA Short Term Debt vs Long Term Investments Analysis
ABIO Stock | USD 3.25 0.24 6.88% |
ARCA Biopharma financial indicator trend analysis is way more than just evaluating ARCA Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ARCA Biopharma is a good investment. Please check the relationship between ARCA Biopharma Short Term Debt and its Long Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.
Short Term Debt vs Long Term Investments
Short Term Debt vs Long Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ARCA Biopharma Short Term Debt account and Long Term Investments. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between ARCA Biopharma's Short Term Debt and Long Term Investments is -0.07. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Long Term Investments in the same time period over historical financial statements of ARCA Biopharma, assuming nothing else is changed. The correlation between historical values of ARCA Biopharma's Short Term Debt and Long Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of ARCA Biopharma are associated (or correlated) with its Long Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Investments has no effect on the direction of Short Term Debt i.e., ARCA Biopharma's Short Term Debt and Long Term Investments go up and down completely randomly.
Correlation Coefficient | -0.07 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Short Term Debt
Long Term Investments
Long Term Investments is an item on the asset side of ARCA Biopharma balance sheet that represents investments ARCA Biopharma intends to hold for over a year. ARCA Biopharma long term investments may include different instruments such as stocks, bonds, real estate and cash.Most indicators from ARCA Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ARCA Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.At this time, ARCA Biopharma's Selling General Administrative is very stable compared to the past year. As of the 2nd of May 2024, Enterprise Value Over EBITDA is likely to grow to 1.82, while Issuance Of Capital Stock is likely to drop 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 13K | 675K | 1.8M | 1.9M | Interest Income | 13K | 675K | 1.8M | 1.9M |
ARCA Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
ARCA Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ARCA Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.5M | 50.4M | 54.9M | 43.1M | 37.9M | 34.9M | |
Other Current Liab | 508K | 1.7M | 2.4M | 798K | 561K | 533.0K | |
Total Current Liabilities | 926K | 3.5M | 3.5M | 1.1M | 637K | 605.2K | |
Total Stockholder Equity | 7.6M | 46.5M | 51.0M | 41.7M | 37.0M | 22.4M | |
Property Plant And Equipment Net | 32K | 449K | 485K | 368K | 257K | 244.2K | |
Net Debt | (8.3M) | (48.7M) | (53.0M) | (42.2M) | (37.2M) | (35.3M) | |
Retained Earnings | (144.4M) | (154.2M) | (173.5M) | (183.4M) | (188.7M) | (198.2M) | |
Accounts Payable | 418K | 1.8M | 1.1M | 334K | 362K | 343.9K | |
Cash | 8.4M | 49.1M | 53.4M | 42.4M | 37.4M | 23.0M | |
Non Current Assets Total | 56K | 461K | 503K | 386K | 269.0K | 255.5K | |
Cash And Short Term Investments | 8.4M | 49.1M | 53.4M | 42.4M | 37.4M | 34.6M | |
Common Stock Shares Outstanding | 1.3M | 4.7M | 13.9M | 14.4M | 14.4M | 15.1M | |
Liabilities And Stockholders Equity | 8.5M | 50.4M | 54.9M | 43.1M | 37.9M | 34.9M | |
Non Current Liabilities Total | 418K | 409K | 383K | 280K | 204.0K | 193.8K | |
Other Current Assets | 117K | 897K | 1.1M | 254K | 161K | 153.0K | |
Other Stockholder Equity | 152.0M | 200.7M | 224.5M | 225.1M | 225.7M | 200.1M | |
Total Liab | 926K | 3.9M | 3.9M | 1.4M | 841K | 799.0K | |
Property Plant And Equipment Gross | 32K | 449K | 680K | 572K | 469K | 445.6K | |
Total Current Assets | 8.5M | 50.0M | 54.4M | 42.7M | 37.6M | 29.0M | |
Property Plant Equipment | 10K | 449K | 485K | 368K | 331.2K | 314.6K | |
Net Tangible Assets | 7.6M | 46.5M | 51.0M | 41.7M | 47.9M | 24.1M | |
Retained Earnings Total Equity | (131.0M) | (138.9M) | (144.4M) | (154.2M) | (138.7M) | (145.7M) | |
Capital Surpluse | 141.3M | 145.0M | 152.0M | 200.7M | 230.8M | 136.2M | |
Net Invested Capital | 7.6M | 46.5M | 51.0M | 41.7M | 37.0M | 31.5M | |
Net Working Capital | 7.6M | 46.5M | 50.9M | 41.6M | 37.0M | 31.4M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ARCA Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ARCA Biopharma's short interest history, or implied volatility extrapolated from ARCA Biopharma options trading.
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with ARCA Stock
0.71 | ELYM | Eliem Therapeutics Trending | PairCorr |
Moving against ARCA Stock
0.91 | PRFX | PainreformLtd | PairCorr |
0.9 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
0.87 | EVOK | Evoke Pharma | PairCorr |
0.85 | GILD | Gilead Sciences | PairCorr |
0.8 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.42) | Return On Assets (0.12) | Return On Equity (0.16) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.